| 24 3.24 (15.61%) | 04-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.02 |
1-year : | 33.9 |
| Resists | First : | 24.85 |
Second : | 29.02 |
| Pivot price | 20.95 |
|||
| Supports | First : | 20.75 |
Second : | 18.22 |
| MAs | MA(5) : | 21.15 |
MA(20) : | 20.61 |
| MA(100) : | 19.84 |
MA(250) : | 20.55 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 46.4 |
D(3) : | 38  |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 37.26 | Low : | 10.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NGNE ] has closed Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.89 - 25.01 | 25.01 - 25.12 |
| Low: | 20.69 - 20.81 | 20.81 - 20.91 |
| Close: | 23.78 - 24 | 24 - 24.2 |
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Wed, 08 Apr 2026
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Wed, 08 Apr 2026
Four new Neurogene hires get options for 69,140 shares - Stock Titan
Mon, 30 Mar 2026
RSU tax sale: Neurogene (NGNE) CMO disposes 828 shares - Stock Titan
Mon, 30 Mar 2026
Neurogene (NGNE) CFO’s 2,558-share sale tied to mandatory RSU tax withholding - Stock Titan
Wed, 25 Mar 2026
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - The Globe and Mail
Tue, 24 Mar 2026
Neurogene: Q4 Earnings Snapshot - 10TV
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 108.7 (%) |
| Shares Short | 3,890 (K) |
| Shares Short P.Month | 3,610 (K) |
| EPS | -4.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -31.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.81 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -5.67 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|